β-LGND2, also known as ERβ-selective ligand 2 or as GTx-878, is a synthetic nonsteroidal estrogen and selective ERβ agonist which was under development by GTx for the treatment of benign prostatic hyperplasia, prostatitis, and rheumatoid arthritis but was never marketed. It shows approximately 25-fold selectivity for activation of the ERβ over the ERα (EC50 = 2 nM and 52 nM, respectively). β-LGND2 is an isoquinolinone derivative.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
foaf:depiction | |
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage |
|
Link from a Wikipage to an external page | |
sameAs | |
dbp:wikiPageUsesTemplate | |
thumbnail | |
br |
|
c |
|
CAS number |
|
CAS supplemental |
|
class |
|
H |
|
IUPAC name |
|
n |
|
O |
|
PubChem |
|
SMILES |
|
StdInChI |
|
StdInChIKey |
|
synonyms |
|
has abstract |
|
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
CAS number |
|
PubChem |
|
class | |
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is Wikipage redirect of | |
is foaf:primaryTopic of |